The Global liquid biopsy market was valued at US$ 4.3 Billion in 2022, and is projected to reach US$ 7.96 Billion by 2030, growing at a CAGR of 23.4% from 2023 to 2030.

Liquid biopsy is a non-invasive diagnostic tool that involves the analysis of biomarkers in body fluids such as blood, urine, or cerebrospinal fluid. It is used to detect cancer and other diseases by analyzing circulating tumor cells, cell-free DNA, and other biomolecules in the blood.

The market growth is driven by factors such as the increasing prevalence of cancer, rising demand for non-invasive diagnostic tools, and advancements in liquid biopsy technologies. The market is segmented by circulating biomarker type, clinical application, end user, and region. Circulating biomarkers include circulating tumor cells, cell-free DNA, exosomes, and other biomolecules. Clinical applications include cancer diagnosis, treatment monitoring, and early detection of cancer recurrence. End users include hospitals and laboratories, academic and research centers, and diagnostic centers.

North America dominates the global liquid biopsy market due to the presence of advanced healthcare infrastructure, increasing investments in research and development, and the high incidence of cancer in the region. However, Asia Pacific is expected to grow at the highest CAGR during the forecast period, driven by the increasing demand for personalized medicine, rising healthcare expenditure, and growing awareness about liquid biopsy technologies.

Market Dynamics

Driving Factors

There are several driving factors contributing to the growth of the global liquid biopsy market. Some of these factors include:

Growing demand for non-invasive diagnostic tools: Liquid biopsy is a non-invasive alternative to traditional diagnostic methods such as tissue biopsies, which are invasive and can cause complications.

Rising healthcare expenditure: Increasing healthcare expenditure in both developed and developing countries is driving the demand for new and innovative diagnostic tools.

Early detection of cancer recurrence: Liquid biopsy can detect cancer recurrence earlier than traditional imaging methods, allowing for earlier intervention and better patient outcomes.

Restraining Factors

There are several factors that may restrain the growth of the global liquid biopsy market. Some of these factors include:

Limited clinical utility: While liquid biopsy has shown promise in the detection and monitoring of cancer, its clinical utility may be limited in certain patient populations or in the context of certain cancer types.

Lack of standardization: There is currently a lack of standardization in liquid biopsy testing, which may make it difficult to compare results across different laboratories and diagnostic platforms.

Limited awareness: Despite growing awareness about liquid biopsy, some patients and healthcare providers may still be unfamiliar with the technology or may not fully understand its benefits.

Challenges Factors

There are several challenges associated with the development and adoption of liquid biopsy technologies. Some of these challenges include:

Reimbursement: Reimbursement policies for liquid biopsy tests may be limited, which may discourage patients and healthcare providers from using these tests.

Cost: Liquid biopsy tests are often more expensive than traditional diagnostic tests, which may limit their adoption in certain healthcare settings or by certain patient populations.

Limited clinical utility: While liquid biopsy has shown promise in the detection and monitoring of cancer, its clinical utility may be limited in certain patient populations or in the context of certain cancer types.

Lack of awareness and education: Despite growing awareness about liquid biopsy, some patients and healthcare providers may still be unfamiliar with the technology or may not fully understand its benefits.

Opportunity Factors

The global liquid biopsy market presents several opportunities for growth and innovation. Some of these opportunities include:

Growing demand for non-invasive testing: As patients and healthcare providers increasingly seek non-invasive testing options, liquid biopsy presents a significant opportunity for growth in the diagnostic testing market.

Emerging markets: As healthcare systems in emerging markets continue to develop, there is significant potential for the adoption of liquid biopsy technologies in these regions.

Segmentation Analysis

Biomaker Outlook

PCR is a technology used to amplify small amounts of DNA for analysis. PCR-based liquid biopsy assays are commonly used for the detection of cancer-related mutations. NGS is a high-throughput sequencing technology used to analyze the entire genome or specific regions of interest. NGS-based liquid biopsy assays are commonly used for the detection and monitoring of cancer.

Understanding the different technologies used in liquid biopsy is critical for companies operating in this space, as it can help them develop and market products that meet the specific needs of healthcare providers and patients. Advances in liquid biopsy technologies are also likely to drive innovation in the market and contribute to its growth in the coming years.

End Use Outlook

Blood is the most commonly used sample type for liquid biopsy, as it is easily accessible and can provide information on both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Urine is a non-invasive sample type that can be used for the detection of certain cancers, such as bladder cancer.

Saliva is another non-invasive sample type that can be used for liquid biopsy analysis, and is being investigated for the detection of a range of diseases, including cancer and infectious diseases. CSF is a sample type that can be used for the detection of central nervous system (CNS) tumors and other CNS-related diseases.

Pleural fluid is a sample type that can be used for the detection of lung cancer and other respiratory-related diseases. Ascites fluid is a sample type that can be used for the detection of ovarian and other abdominal-related cancers.

Regional Analysis

North America is currently the largest market for liquid biopsy, driven by the presence of a well-established healthcare infrastructure and strong investment in research and development. The region is expected to continue to dominate the market in the coming years.

Europe is also a significant market for liquid biopsy, driven by the presence of leading biotechnology and pharmaceutical companies. The market in Europe is expected to grow at a steady pace in the coming years.

The Asia-Pacific region is expected to be the fastest-growing market for liquid biopsy, driven by the increasing incidence of cancer and other chronic diseases, growing investment in healthcare infrastructure, and rising awareness of liquid biopsy technology.

Regional markets for liquid biopsy are shaped by factors such as healthcare infrastructure, regulatory environment, investment in research and development, and awareness of liquid biopsy technology. Understanding the dynamics of regional markets is critical for companies looking to enter or expand in the liquid biopsy market.

Scope Of Report:

The Global Liquid Biopsy Market has been segmented into:

By Sample Type

• Blood Sample-based
• Others

By Biomarker

• Circulating Nucleic Acids
• CTC
• Exosomes/Microvesicles
• Circulating Proteins

By Technology

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

By Region

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Market Players 

The global liquid biopsy market is highly competitive and fragmented, with numerous players vying for market share. Some of the key companies in the market are:

• QIAGEN
• Myriad Genetics, Inc.
• BIOCEPT, Inc.
• Guardant Health, Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Angle plc
• Oncimmune
• Thermo Fisher Scientific, Inc.
• Lucence health Inc.
• FreenomeHoldings, Inc.
• EPIGENOMICS AG

The global liquid biopsy market is highly competitive, with a large number of companies operating in this space. Some of the key players in the market include:

Guardant Health is a leading player in the liquid biopsy market, offering a range of liquid biopsy products for the detection and monitoring of cancer. QIAGEN is a biotechnology company that offers liquid biopsy products for the detection of cancer and infectious diseases.

Roche Diagnostics is a global leader in the diagnostic testing market, offering a range of liquid biopsy products for cancer detection and monitoring. Biocept is a molecular diagnostics company that offers liquid biopsy products for the detection and monitoring of cancer.

Natera is a biotechnology company that offers liquid biopsy products for the detection of cancer and genetic disorders. Trovagene is a molecular diagnostics company that offers liquid biopsy products for the detection and monitoring of cancer.

Sysmex Corporation is a global leader in the diagnostic testing market, offering a range of liquid biopsy products for cancer detection and monitoring. Cynvenio Biosystems is a molecular diagnostics company that offers liquid biopsy products for cancer detection and monitoring.

Personal Genome Diagnostics is a biotechnology company that offers liquid biopsy products for the detection and monitoring of cancer. F. Hoffmann-La Roche AG is a global pharmaceutical company that offers liquid biopsy products for cancer detection and monitoring.

Strategic Developments

In 2021, Guardant Health acquired Bellwether Bio, a company focused on developing liquid biopsy assays for the early detection of cancer.

In 2020, QIAGEN announced a collaboration with Ares Genetics to develop and commercialize a next-generation sequencing-based test for the detection of antibiotic-resistant bacteria in blood cultures.

In 2020, Roche Diagnostics announced the launch of its Elecsys® EGFR Mutation Test v2, a liquid biopsy test for the detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients.

In 2020, Biocept entered into a collaboration with Aegea Biotechnologies to develop a liquid biopsy test for the detection of the SARS-CoV-2 virus.

In 2019, Natera acquired Signatera, a company focused on developing personalized liquid biopsy assays for cancer detection and monitoring.

In 2019, Trovagene announced the launch of its Precision Cancer Monitoring® platform, a liquid biopsy technology for the detection and monitoring of cancer.

In 2018, Sysmex Corporation acquired Silicon Valley-based company, Oxford Gene Technology, to expand its genetic analysis business, including liquid biopsy products.

In 2018, Cynvenio Biosystems announced a partnership with Menarini Silicon Biosystems to develop and commercialize a liquid biopsy test for the detection and monitoring of cancer.